Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 8;9:7072. doi: 10.1038/s41598-019-43430-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Rho/MRTF inhibitor CCG-222740 decreases the level of macrophages and increases CD4 T cells in the pancreas of KC mice stimulated with caerulein. Levels of CD45⁺, CD3⁺, CD4⁺ T cells (A - CD4 T cells, n = 7 per group) and CD45⁺, CD11b⁺, Gr1⁻ or F4/80⁺ cells (B – macrophages, n = 6 per group) were analyzed by flow cytometry and immunohistochemistry in the pancreas. Scale bar: 60 μm. (C) Levels of cytokines including IL-7 were determined by a cytokine multiplex assay in pancreas lysates (n = 7 per group). *p < 0.05, Caerulein 75 μg/kg vs CCG-222740 treatment.